| 2026-06-12 17:01 |
8-K |
["1.01", "5.02"] |
material agreement |
0.62
|
Strategic investment in cannabinoid company with M&A-experienced COO; management discussing potential future transactions with investee. |
SEC · detail |
| 2026-06-04 16:30 |
8-K |
["3.02"] |
other |
0.05
|
Routine unregistered equity sale under existing ELOC agreement; no M&A signals. |
SEC · detail |
| 2026-06-03 08:45 |
8-K |
["7.01", "9.01"] |
strategic review |
0.65
|
8-K references press release on strategic transaction initiatives; press release content not provided in excerpt. |
SEC · detail |
| 2026-05-15 08:59 |
8-K |
["5.02", "7.01", "9.01"] |
officer change |
0.35
|
CEO departure and interim replacement; weak M&A signal absent strategic review or transaction language. |
SEC · detail |
| 2026-04-27 16:30 |
8-K |
["5.02"] |
officer change |
0.35
|
Board appointment of experienced CXO with M&A/restructuring background; insufficient evidence of active transaction. |
SEC · detail |
| 2026-04-24 16:30 |
8-K |
["1.01", "5.02", "8.01"] |
material agreement |
0.72
|
Stock option vesting contingent on acquisition of Medterra CBD, LLC suggests M&A exploration. |
SEC · detail |